Minimizing and Managing Toxicities From BTK Inhibitor Therapy: An Interactive Tool to Optimize the Therapeutic Benefit for Patients

Download All
Learn how the experts would manage toxicities associated with BTK inhibitor therapies with our newly updated Interactive Decision Support Tool. Then gain multidisciplinary insights into toxicity prevention and management with downloadable slides, expert commentary, and an informational resource aimed at patients and caregivers.
Farrukh T. Awan, MD
Beth Faiman, PhD, MSN, APRN-BC, AOCN
Christopher R. Flowers, MD, MS
Nicole Lamanna, MD
John P. Leonard, MD
Anthony Perissinotti, PharmD, BCOP
Julie M. Vose, MD, MBA

BTK Adverse Event Management Support Tool

Use this Interactive Decision Support Tool to learn strategies to assess and manage adverse events associated with BTK inhibitors from 5 experts in managing patients with hematologic malignancies.

Farrukh T. Awan, MD Christopher R. Flowers, MD, MS Nicole Lamanna, MD John P. Leonard, MD Julie M. Vose, MD, MBA Released: December 6, 2021

ClinicalThought

How can nurses and other frontline healthcare professionals best counsel patients who are starting BTK inhibitors? In this commentary, I share key safety and adherence considerations to emphasize when educating patients and caregivers.

Beth Faiman, PhD, MSN, APRN-BC, AOCN Released: July 15, 2021

Downloadable Patient and Caregiver Support Resource

Download this accessible resource developed for patients and caregivers on side effect care when receiving acalabrutinib, ibrutinib, or zanubrutinib.

Anthony Perissinotti, PharmD, BCOP Released: August 25, 2021

Text Module

Review an expert’s perspective on BTK inhibitor selection for patients with B-cell malignancies and various comorbidities, and then get up to date on multidisciplinary management of common and rare toxicities.

Christopher R. Flowers, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: September 29, 2021 Expired: September 28, 2022

Download these slides for expert strategies on monitoring for and managing toxicities associated with BTK inhibitor therapy in patients with B-cell malignancies.

Christopher R. Flowers, MD, MS Released: September 29, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
BeiGene, Ltd.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings